Prime Medicine

Prime Medicine, Inc., a US biotechnology company developing gene editing therapies, is seeing interest in its stock, with traders checking its latest price, quotes and market history. PRME remains a closely watched name among investors following developments around its precision editing pipeline, although no specific new corporate announcement is attached to the current attention.